News Brief: Biosimilar Udenyca Now Available
January 7, 2019
According to news reports, Coherus BioSciences, Inc., has marketed Udenyca (pegfilgrastim-cbqv), the second biosimilar to Neulasta (pegfilgrastim; Amgen). The Food and Drug Administration (FDA) approved Udenyca on November 5, 2018.
Udenyca is the seventh biosimilar to be marketed in the United States.
Coherus previously announced that it would launch Udenyca at a list price of $4,175 per unit. This represents a 33% discount on the list price of Neulasta and matches the list price of Fulphila (pegfilgrastim-jmdb; Mylan), the first pegfilgrastim biosimilar approved in the United States.
The product launch was reported by The Center for Biosimilars.